

## **IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.**

Ganchimeg Ishdorj,<sup>1\*</sup> Erin Streu,<sup>2\*</sup> Pascal Lambert,<sup>3</sup> Dhali Dhaliwal,<sup>4</sup> Salaheddin M. Mahmud,<sup>6,7</sup> Spencer B. Gibson,<sup>1,8,9</sup> Versha Banerji,<sup>1,4</sup> Aaron J. Marshall<sup>9</sup> and James B. Johnston<sup>1,4</sup>

<sup>1</sup>Research Institute in Oncology and Hematology (formerly Manitoba Institute of Cell Biology), CancerCare Manitoba Winnipeg, Manitoba, Canada

<sup>2</sup>Department of Nursing, CancerCare Manitoba Winnipeg, Manitoba, Canada

<sup>3</sup>Department of Epidemiology, CancerCare Manitoba Winnipeg, Manitoba, Canada

<sup>4</sup>Section of Haematology/Oncology, Department of Internal Medicine, University of Manitoba Winnipeg, Manitoba, Canada

<sup>5</sup>Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

<sup>6</sup>Vaccine and Drug Evaluation Centre, University of Manitoba, Winnipeg, Manitoba, Canada

<sup>7</sup>College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada

<sup>8</sup>Department of Biochemistry and Medical Genetics, University of Manitoba Winnipeg, Manitoba, Canada

<sup>9</sup>Department of Immunology, University of Manitoba

\*G.I. and E.S. contributed equally to this work

**Correspondence to:** James B. Johnston, MB, BAO, FRCP(C), Section of Hematology/Oncology, Department of Internal Medicine, University of Manitoba, CancerCare Manitoba, 675, McDermot Avenue, Winnipeg, Manitoba, Canada.

Phone : (204) 787-2161

Fax : (204) 787-2190

E-mail: [james.johnston@cancercare.mb.ca](mailto:james.johnston@cancercare.mb.ca)

**Short title:** Immunoglobulin subtypes and CLL

**Supplementary Table 1. Competing risk regression predicting treatment of CLL/SLL**

Variables		Unimputed model						Imputed model					
		Univariable			Multivariable			Univariable			Multivariable		
		SHR	CI, 95%	P value	SHR	CI, 95%	P value	SHR	CI, 95%	P value	SHR	CI, 95%	P value
<b>IgG</b>	*IgG <sup>0.5</sup>	3.05	1.34 - 6.96	<0.001				2.19	1.42 - 3.37	0.001			
	IgG <sup>-1</sup>	1.69	1.30 - 2.20					1.16	0.98 - 1.38				
<b>IgA</b>	**IgA <sup>0.5</sup>	<b>0.13</b>	<b>0.07 - 0.22</b>	<0.001	0.56	0.29 - 1.09	0.008	0.18	0.10 - 0.32	<0.001	0.34	<b>0.18 - 0.64</b>	0.001
	IgA <sup>2</sup>	1.16	1.11 - 1.21		1.07	1.02 - 1.12		1.13	1.08 - 1.19		1.09	1.04 - 1.14	
<b>IgM</b>	IgM <sup>-1</sup>	1.07	1.03 - 1.12	0.001	1.05	1.00 - 1.11	0.036	1.07	1.03 - 1.11	0.001			
<b>Gender</b>	Female	0.97	0.77 - 1.21	0.764				0.97	0.77 - 1.21	0.764			
	Male	1			1								
<b>CIRS</b>	Continuous	1.05	1.01 - 1.09	0.010				1.05	1.01 - 1.09	0.010			
<b>Age</b>	Continuous	0.99	0.99 - 1.00	0.266				0.99	0.99 - 1.00	0.266			
<b>CD38</b>	Missing	1.32	0.94 - 1.86	<0.001	0.96	0.60 - 1.54	0.004			<0.001			
	Positive	2.55	1.99 - 3.27		1.70	1.23 - 2.36		2.43	1.89 - 3.11				
	Negative	1			1			1					
<b>ZAP-70</b>	Missing	1.37	1.00 - 1.88	<0.001						<0.001			
	Positive	2.23	1.74 - 2.86				2.15	1.67 - 2.77					
	Negative	1			1								
<b>IGHV gene</b>	No result	0.86	0.45 - 1.66	0.046						0.153			
	VH6	0.72	0.23 - 2.26				0.87	0.25 - 2.97					
	VH5	1.08	0.48 - 2.42				1.31	0.52 - 3.28					
	VH4	0.93	0.46 - 1.91				1.07	0.49 - 2.37					
	VH3	0.99	0.52 - 1.88				1.13	0.54 - 2.36					
	VH2	1					1						
<b>IGHV</b>	No result	1.45	1.06 - 1.97	<0.001	1.39	0.65 - 2.98	<0.001			<0.001			
	Unmutated	3.42	2.63 - 4.46		2.49	1.73 - 3.58		3.52	2.70 - 4.60				
	Mutated	1			1			1					
<b>B2M</b>	Missing	1.73	1.23 - 2.44	<0.001	0.75	0.41 - 1.37	0.004			<0.001			
	High	2.49	1.92 - 3.23		1.54	1.13 - 2.11		2.24	1.75 - 2.87				
	Normal	1			1			1					
<b>M- band</b>	Missing	0.93	0.71 - 1.22	0.281				0.93	0.71 - 1.22	0.281			
	Oligoclonal	1.60	0.69 - 3.74				1.60	0.69 - 3.74					
	Present	1.20	0.84 - 1.71				1.20	0.84 - 1.71					
	Not present	1					1						
<b>SLL MBL CLL, stages</b>		9.92	4.83 - 20.36	<0.001	6.18	3.10 - 12.31	<0.001	9.92	4.83 - 20.36	<0.001	7.32	3.58 - 14.99	<0.001
	0	1			1			1					
	I-II	3.56	1.78 - 7.12		2.28	1.18 - 4.42		3.56	1.78 - 7.12				
	III-IV	10.79	5.41 - 21.51		5.68	2.93 - 11.01		10.79	5.41 - 21.51				
		17.75	8.24 - 38.20		15.60	6.46 - 37.70		17.75	8.24 - 38.20		12.24	<b>5.50 - 27.25</b>	
<b>Diagnosis Year</b>	Continuous	0.98	0.95 - 1.02	0.442				0.98	0.95 - 1.02	0.442			

\* IgG<sup>-1</sup> and IgG<sup>0.5</sup>, means that IgG was entered as two variables where the one is the power of -1, and the other was to the power of 0.5.

\*\*IgA entered as two variables where one was to the power of 0.5 and the other was to the power of 2.

**Supplementary Table 2. Cox regression predicting overall survival**

Variables		Unimputed model						Imputed model					
		Univariable			Multivariable			Univariable			Multivariable		
		SHR	CI, 95%	P value	SHR	CI, 95%	P value	SHR	CI, 95%	P value	SHR	CI, 95%	P value
<b>IgG</b>		1.01	0.99 - 1.03	0.309				1.01	0.99 - 1.03	0.339			
<b>IgA</b>	*IgA^1	0.62	0.47 - 0.81	<0.001				0.65	0.49 - 0.85	<0.001	0.81	<b>0.61 - 1.08</b>	0.026
	IgA^3	1.03	1.02 - 1.04					1.03	1.02 - 1.04		1.01	1.00 - 1.03	
<b>IgM</b>		1.04	0.98 - 1.10	0.202				1.03	0.97 - 1.10	0.332			
<b>Gender</b>	Female	0.67	0.49 - 0.92	0.013	0.55	0.39 - 0.76	<0.001	0.67	0.49 - 0.92	0.013	0.52	0.38 - 0.73	<0.001
	Male	1			1			1			1		
<b>CIRS</b>	(CIRS+1)^1	1.40	1.15 - 1.71	<0.001				1.40	1.15 - 1.71	<0.001			
	(CIRS+1)^2	0.98	0.97 - 1.00					0.98	0.97 - 1.00				
<b>Age</b>	(Age/50)^3	1.79	1.61 - 2.00	<0.001	1.78	1.58 - 2.02	<0.001	1.79	1.61 - 2.00	<0.001	1.72	1.52 - 1.95	<0.001
<b>CD38</b>	Missing	2.24	1.53 - 3.28	<0.001	1.83	1.18 - 2.83	0.023						
	Positive	1.91	1.36 - 2.67		1.30	0.90 - 1.88		1.86	1.33 - 2.59	<0.001			
	Negative	1			1			1					
<b>ZAP-70</b>	Missing	2.20	1.56 - 3.10	<0.001	1.71	1.15 - 2.53	0.001						
	Positive	1.19	0.82 - 1.73		0.73	0.49 - 1.09		1.17	0.81 - 1.68	0.403			
	Negative	1			1			1					
<b>IGHV gene</b>	No result	5.25	1.29 - 21.34	<0.001									
	VH6	2.04	0.34 - 12.19					1.67	0.28 - 10.02	0.786			
	VH5	1.94	0.38 - 10.01					1.66	0.33 - 8.39				
	VH4	2.22	0.50 - 9.75					2.01	0.47 - 8.50				
	VH3	2.41	0.59 - 9.89					2.28	0.59 - 8.75				
	VH2	1						1					
VH1	2.97	0.71 - 12.46				2.51	0.66 - 9.60						
<b>IGHV</b>	No result	2.97	2.05 - 4.31	<0.001									
	Unmutated	1.86	1.25 - 2.76					1.93	1.31 - 2.86	0.001			
	Mutated	1						1					
<b>B2M</b>	Missing	3.06	1.70 - 5.51	<0.001	1.85	1.01 - 3.40	<0.001						
	High	6.79	4.14 - 11.11		3.07	1.84 - 5.12		5.59	3.50 - 8.93	<0.001	3.01	1.84 - 4.92	<0.001
	Low-normal	1			1			1			1		
<b>M-band</b>	Missing	1.01	0.70 - 1.47	0.005				1.01	0.70 - 1.47	0.005			
	Oligoclonal	2.19	0.98 - 4.87					2.19	0.98 - 4.87				
	Present	1.76	1.15 - 2.68					1.76	1.15 - 2.68				
	Not present	1						1					
<b>CLL, stages</b>	<b>SLL</b>	2.01	0.99 - 4.08	<0.001	1.08	0.51 - 2.30	0.007	2.01	0.99 - 4.08	<0.001	1.32	0.62 - 2.78	0.045
	<b>MBL</b>	1			1			1			1		
	0	1.33	0.70 - 2.53		1.04	0.54 - 2.02		1.33	0.70 - 2.53		1.03	0.53 - 1.99	
	I-II	2.29	1.20 - 4.37		1.66	0.83 - 3.32		2.29	1.20 - 4.37		1.50	0.75 - 3.00	
	III-IV	4.92	2.43 - 9.96		2.38	1.12 - 5.10		4.92	2.43 - 9.97		2.21	<b>1.03 - 4.78</b>	
<b>IgG replacement</b>	Yes	1.13	0.55 - 2.33	0.738				1.13	0.55 - 2.33	0.738			
	No	1						1					
<b>CLL treatment</b>	Yes	3.05	2.23 - 4.17	<0.001	1.96	1.37 - 2.79	<0.001	3.05	2.23 - 4.17	<0.001	1.83	1.29 - 2.59	0.001
	No	1			1			1			1		
<b>Diagnosis year</b>	Continuous	1.02	0.96 - 1.08	0.540				1.02	0.96 - 1.08	0.540			

\*IgA entered as two variables where one was to the power of 1, and the other was to the power of 3.

**Supplementary Table 3. Competing risk regression predicting IgG replacement therapy.**

Variables		Unimputed model						Imputed model					
		Univariable			Multivariable			Univariable			Multivariable		
		SHR	CI, 95%	P value	SHR	CI, 95%	P value	SHR	CI, 95%	P value	SHR	CI, 95%	P value
<b>IgG</b>	(IgG/10) <sup>-2</sup>	2.44	1.55 - 3.85	<0.001	2.28	1.44 - 3.60	<0.001	2.11	1.30 - 3.41	<0.001	1.68	<b>1.04 - 2.70</b>	<b>0.047</b>
	(IgG/10) <sup>-2</sup> * ln(IgG/10)	1.62	1.21 - 2.16		1.56	1.17 - 2.09		1.50	1.10 - 2.04		1.32	0.98 - 1.77	
<b>IgA</b>		0.41	0.23 - 0.72	0.002				0.46	0.28 - 0.75	0.002	0.54	0.31 - 0.95	0.031
<b>IgM</b>	log(IgM)	0.53	0.36 - 0.78	0.001				0.55	0.38 - 0.80	0.002			
<b>Gender</b>	Female	0.97	0.55 - 1.73	0.919				0.97	0.55 - 1.73	0.919			
	Male	1			1								
<b>CIRS</b>		1.19	1.10 - 1.29	<0.001	1.22	1.11 - 1.35	<0.001	1.19	1.10 - 1.29	<0.001	1.24	1.14 - 1.36	<0.001
<b>Age</b>	per 10 years	0.73	0.59 - 0.92	0.006	0.66	0.50 - 0.88	0.005	0.73	0.59 - 0.92	0.006	0.64	0.50 - 0.83	0.001
<b>CD38</b>	Missing	0.94	0.39 - 2.31	0.128				1.71	0.94 - 3.12	0.082			
	Positive	1.80	0.98 - 3.30		1								
	Negative	1											
<b>ZAP-70</b>	Missing	0.11	0.01 - 0.79	0.004				1.92	1.08 - 3.42	0.026			
	Positive	1.91	1.08 - 3.37		1								
	Negative	1											
<b>IGHV</b>	No result	0.92	0.45 - 1.86	0.583				1.32	0.69 - 2.44	0.404			
	Unmutated	1.30	0.68 - 2.48		1								
	Mutated	1											
<b>B2M</b>	Missing	1.30	0.56 - 3.02	0.439				1.37	0.72 - 2.61	0.341			
	High	1.57	0.79 - 3.13		1								
	Low-normal	1											
<b>SLL</b> <b>MBL</b> <b>CLL, stage</b>		0.77	0.19 - 3.04	0.034				0.77	0.19 - 3.04	0.034			
		1			1								
	0	0.83	0.28 - 2.50		0.83	0.28 - 2.50							
	I-II	1.91	0.64 - 5.68		1.91	0.64 - 5.68							
	III-IV	2.50	0.74 - 8.40		2.50	0.74 - 8.40							
<b>CLL Treatment</b>	Yes	2.84	1.57 - 5.13	0.001	2.97	1.46 - 6.04	0.003	2.84	1.57 - 5.13	0.001	2.60	1.42 - 4.76	0.002
	No	1		1			1		1		1		